(NASDAQ: GOSS) Gossamer Bio's forecast annual revenue growth rate of 84.5% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.96%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.07%.
Gossamer Bio's revenue in 2026 is $44,051,000.On average, 10 Wall Street analysts forecast GOSS's revenue for 2026 to be $10,599,307,375, with the lowest GOSS revenue forecast at $0, and the highest GOSS revenue forecast at $29,260,698,746. On average, 10 Wall Street analysts forecast GOSS's revenue for 2027 to be $30,836,915,788, with the lowest GOSS revenue forecast at $14,759,039,046, and the highest GOSS revenue forecast at $54,723,200,478.
In 2028, GOSS is forecast to generate $67,272,758,191 in revenue, with the lowest revenue forecast at $40,287,274,353 and the highest revenue forecast at $86,087,836,509.